| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8441272 | European Journal of Cancer | 2016 | 8 Pages |
Abstract
In a subgroup analysis of the adjuvant TEACH trial, we show that anti-HER2 monotherapy with a TKI is beneficial as adjuvant therapy in a subgroup of patients. NNT in HER2+ HR- patients are in range with those reported from up-front adjuvant trastuzumab trials.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Kathrin Strasser-Weippl, Nora Horick, Ian E. Smith, Joyce O'Shaughnessy, Bent Ejlertsen, Frances Boyle, Aman U. Buzdar, Pierre Fumoleau, William Gradishar, Miguel Martin, Beverly Moy, Martine Piccart-Gebhart, Kathleen I. Pritchard, Deborah Lindquist,